In just a few days, Obesity Week 2024 will kick off in San Antonio, Texas.
In fact, the “preeminent international conference for obesity researchers and clinicians, ObesityWeek is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy,” says The Obesity Society.
It's also where some of the top obesity companies will present their latest data.
|
Company: Viking Therapeutics (SYM: VKTX)
Look at Viking Therapeutics (SYM: VKTX), for example. The company is set to provide results from its Phase 2 VENTURE clinical trial with its subcutaneous formulation of VK2735. It’s other presentation will highlight results from its Phase 1 multiple ascending dose clinical trial of its oral formulation of VK2735. |
InvestorPlace
Buffett, Bloomberg, & 48 Congress Members Are Buying ONE Sector
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy?
And why are they all piling into ONE unique corner of the market…
The last time we saw the world's wealthiest investors move their cash into this corner of the market, Stocks exploded 2,020%, 5,609% Even as high as 8,437% in just ONE year. Now, it's all happening again.
Click here for the details.
|
Company: Fractyl Health (SYM: GUTS) Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), announced that it will present weight maintenance data from both its Revita and Rejuva platforms at the meeting, too. The company also notes that, “A pivotal study of Revita in weight maintenance for patients with obesity after discontinuation of GLP-1-based drugs, called REMAIN-1, is underway with anticipated data readouts from the open-label study in weight maintenance in the fourth quarter of 2024 and an anticipated mid-point analysis of the REMAIN-1 in the second quarter of 2025. A pivotal study of Revita in patients with T2D who are inadequately controlled on any glucose lowering agent, REVITALIZE-1, is currently enrolling in the United States and Europe.” |
Mode Mobile
The World's Most Accessible Income-Generating Asset: 7 Billion Consumers